PMID- 26010450
OWN - NLM
STAT- MEDLINE
DCOM- 20160427
LR  - 20180501
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 5
DP  - 2015
TI  - Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight 
      Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
PG  - e0128032
LID - 10.1371/journal.pone.0128032 [doi]
AB  - CONTEXT: The preferred treatment for osteoporosis in men is debated, and pairwise
      meta-analysis cannot obtain hierarchies of these treatments. OBJECTIVE: The
      objective of this study was to integrate the evidence and provide hierarchies of 
      eight drugs based on their effect on the bone mineral density in the lumbar spine
      (BMD in LS) and the fracture rate. DATA SOURCES: Eligible studies were identified
      by searching Amed, British Nursing Index, EMBASE, PubMed, the Cochrane Central
      Register of Controlled Trials (CENTRAL), Google Scholar, SIGLE, the National
      Technical Information Service, the National Research Register (UK), and the
      Current Controlled Trials databases. STUDY SELECTION: RCTs or quasi-RCTs
      reporting at least two drugs (two active drugs or one active drug and a placebo) 
      used to treat osteoporosis in men were selected by two authors. DATA EXTRACTION: 
      Two authors independently extracted the data. DATA SYNTHESIS: Thirteen studies
      involving 3647 patients were included. Compared with placebo therapy, zoledronate
      (SMDs 13.48, 95% credible intervals 11.88-15.08) yielded the most significant
      effect on increasing the BMD in LS, followed by alendronate (11.04, 9.68-12.41), 
      teriparatide (20mcg) + risedronate (10.98, 8.55-13.48), risedronate (10.33,
      8.68-12.01), teriparatide (20mcg) (9.33, 6.87-11.76), strontium ranelate (8.88,
      7.51-10.24), ibandronate (5.49, 3.82-7.16), parathyroid hormone (1-84) (4.89,
      3.12-6.62) and alfacalcidol (3.42, 1.7-5.2). Placebo therapy had a significantly 
      higher fracture rate in contrast to risedronate (OR 2.51, 95% CrI 1.23-4.24) or
      zoledronate (2.92, 1.29-5.62) or teriparatide (20mcg) (4.04, 1.36-8.49) or
      teriparatide (40mcg) (3.5, 1.14-8.34). Zoledronate ranked first for increasing
      the BMD in LS, and teriparatide (20mg) was ranked first for decreasing the
      fracture rate. CONCLUSIONS: Zoledronate might be the best choice to increase the 
      BMD in LS and teriparatide (20mg) might lead to the lowest fracture rate.
FAU - Chen, Ling-Xiao
AU  - Chen LX
AD  - Department of Orthopaedics, Tianjin Medical University General Hospital, 154
      Anshan Road, Heping District, Tianjin, People's Republic of China.
FAU - Zhou, Zhi-Rui
AU  - Zhou ZR
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center,
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China.
FAU - Li, Yu-Lin
AU  - Li YL
AD  - Department of Orthopaedics, Tianjin Medical University General Hospital, 154
      Anshan Road, Heping District, Tianjin, People's Republic of China.
FAU - Ning, Guang-Zhi
AU  - Ning GZ
AD  - Department of Orthopaedics, Tianjin Medical University General Hospital, 154
      Anshan Road, Heping District, Tianjin, People's Republic of China.
FAU - Zhang, Tian-Song
AU  - Zhang TS
AD  - Internal medicine of traditional Chinese medicine department, Jing 'an district
      central hospital of Shanghai, NO. 259, Xikang road, 200040, Shanghai, P.R. China.
FAU - Zhang, Di
AU  - Zhang D
AD  - Department of Orthopaedics, Tianjin Medical University General Hospital, 154
      Anshan Road, Heping District, Tianjin, People's Republic of China.
FAU - Feng, Shi-Qing
AU  - Feng SQ
AD  - Department of Orthopaedics, Tianjin Medical University General Hospital, 154
      Anshan Road, Heping District, Tianjin, People's Republic of China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150526
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Hydroxycholecalciferols)
RN  - 0 (Imidazoles)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Thiophenes)
RN  - 04NQ160FRU (strontium ranelate)
RN  - 10T9CSU89I (Teriparatide)
RN  - 6XC1PAD3KF (zoledronic acid)
RN  - OFG5EXG60L (Risedronate Sodium)
RN  - UMD7G2653W (ibandronic acid)
RN  - URQ2517572 (alfacalcidol)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Alendronate/administration & dosage/adverse effects
MH  - Bone Density/*drug effects
MH  - Bone Density Conservation Agents/*administration & dosage/adverse effects
MH  - Diphosphonates/administration & dosage/adverse effects
MH  - Fractures, Bone/*chemically induced/epidemiology
MH  - Humans
MH  - Hydroxycholecalciferols/administration & dosage/adverse effects
MH  - Imidazoles/administration & dosage/adverse effects
MH  - Lumbar Vertebrae/drug effects/*injuries
MH  - Osteoporosis/complications/*drug therapy
MH  - Parathyroid Hormone/administration & dosage/adverse effects
MH  - Risedronate Sodium/administration & dosage/adverse effects
MH  - Teriparatide/administration & dosage/adverse effects
MH  - Thiophenes/administration & dosage/adverse effects
PMC - PMC4444106
EDAT- 2015/05/27 06:00
MHDA- 2016/04/28 06:00
CRDT- 2015/05/27 06:00
PHST- 2014/11/10 00:00 [received]
PHST- 2015/04/21 00:00 [accepted]
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2016/04/28 06:00 [medline]
AID - 10.1371/journal.pone.0128032 [doi]
AID - PONE-D-14-50581 [pii]
PST - epublish
SO  - PLoS One. 2015 May 26;10(5):e0128032. doi: 10.1371/journal.pone.0128032.
      eCollection 2015.